Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1978 1
1982 3
1988 1
1997 1
1998 2
1999 3
2000 1
2001 5
2002 7
2003 5
2004 12
2005 12
2006 15
2007 13
2008 10
2009 13
2010 19
2011 17
2012 35
2013 39
2014 34
2015 20
2016 28
2017 22
2018 16
2019 19
2020 27
2021 32
Text availability
Article attribute
Article type
Publication date

Search Results

373 results
Results by year
Filters applied: . Clear all
Page 1
Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity.
Wilson WH, O'Connor OA, Czuczman MS, LaCasce AS, Gerecitano JF, Leonard JP, Tulpule A, Dunleavy K, Xiong H, Chiu YL, Cui Y, Busman T, Elmore SW, Rosenberg SH, Krivoshik AP, Enschede SH, Humerickhouse RA. Wilson WH, et al. Among authors: chiu yl. Lancet Oncol. 2010 Dec;11(12):1149-59. doi: 10.1016/S1470-2045(10)70261-8. Epub 2010 Nov 18. Lancet Oncol. 2010. PMID: 21094089 Free PMC article. Clinical Trial.
APOBEC3G: an intracellular centurion.
Chiu YL, Greene WC. Chiu YL, et al. Philos Trans R Soc Lond B Biol Sci. 2009 Mar 12;364(1517):689-703. doi: 10.1098/rstb.2008.0193. Philos Trans R Soc Lond B Biol Sci. 2009. PMID: 19008196 Free PMC article. Review.
Author response.
Gerber LM, Mamtani R, Chiu YL, Bener A, Murphy M, Cheema S, Verjee M. Gerber LM, et al. Among authors: chiu yl. East Mediterr Health J. 2015 May;21(5):360. East Mediterr Health J. 2015. PMID: 26863690 No abstract available.
373 results